公开(公告)号：US11834432B2

公开(公告)日：2023-12-05

申请号：US15998927

申请日：2017-02-17

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Ao Zhang ,  Meiyu Geng ,  Li Xing ,  Jing Ai ,  Zilan Song ,  Xia Peng ,  Wangting Gu ,  Jian Ding

IPC: C07D213/75 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  A61P35/00 ,  A61K31/4427 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4433 ,  A61K31/4409 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5355 ,  A61K31/5377 ,  A61K31/4545 ,  A61K31/44

CPC classification number: C07D401/12 ,  A61P35/00 ,  C07D213/75 ,  C07D403/12 ,  C07D405/12 ,  C07D413/14 ,  C07D417/14

Abstract: Provided in the present invention are a substituted amino six-membered nitric heterocyclic ring compound and a preparation and use thereof. In particular, provided in the present invention is a compound as shown by general formula (I) below, wherein the definition of each group is as described in the description. The compound of the present invention has an excellent tyrosine kinase inhibitory activity, and can thus be used to prepare a series of medicines for treating diseases related to tyrosine kinase inhibitory activity.